GLP-1 Patient Screening and Eligibility at Med Spas: Who Qualifies, Who Does Not, and How to Prove It

Screening Is the Decision Everything Else Rests On

Ask an operator what their weight-loss program consists of and you will usually hear about the medication, the pricing, and the follow-up cadence. Ask a board investigator what they looked at and you will hear about the intake.

There is a reason for the mismatch. Once a patient is on therapy, most of what follows is protocol: titrate on a schedule, watch for tolerance, adjust. The one genuinely discretionary act in the whole program is the decision to start — and that decision is the one a regulator, a plaintiff's expert, or a malpractice carrier will reconstruct years later from whatever you wrote down at the time.

A good screening record does three jobs at once. It establishes that a real clinician evaluated a real person. It shows the specific facts that made this therapy appropriate for that person. And it demonstrates, by the presence of considered exclusions, that the answer could have been no. A file full of approvals with no visible reasoning reads as a sales process wearing clinical clothing, whatever the underlying care was actually like.

This article covers the screening layer only. For the wider regulatory framework — who may prescribe, how product is sourced, how programs are structured — see our GLP-1 compliance guide for med spas.

The Eligibility Criteria, and What They Actually Mean

The approved indications for chronic weight management are consistent across the class. A patient qualifies at a body mass index of 30 kg/m² or greater, or at 27 kg/m² or greater in the presence of at least one weight-related comorbid condition. The comorbidity list that regulators and payers work from includes type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, and established cardiovascular disease.

Three things about that sentence get practices into trouble.

The BMI must be measured, not reported

A height and weight the patient typed into an online form is not a clinical measurement. Where the encounter is remote, the chart should record how the values were obtained and, ideally, corroborate them at the first in-person visit. The single most damaging documentary finding in this area is a cohort of patients whose recorded BMI sits at 27.1 or 30.1 with suspicious regularity. Investigators run that distribution, and a cluster just above the threshold invites the conclusion that the number was worked backwards from the desired answer.

The comorbidity must be established, not assumed

"Patient reports high blood pressure" is not the same as a documented diagnosis of hypertension. For the 27–29.9 band, the comorbidity is doing the entire work of qualifying the patient, so it needs a basis: a measured blood pressure across visits, a laboratory value, a sleep study, a prior diagnosis obtained from the treating clinician, or a current prescription for the condition. Record which one you relied on.

The indication differs between products

Some products in this class are approved for chronic weight management and some are approved for type 2 diabetes. Prescribing a diabetes-indicated product for weight loss is off-label prescribing. Off-label prescribing is lawful and often appropriate, but it is not invisible: it requires a documented clinical rationale and it belongs in the consent conversation. Practices that use the terms interchangeably in their charts and their marketing create an inconsistency that is easy to find and hard to explain.

Building the Intake: What to Collect Before Anyone Is Approved

An intake that supports a defensible decision collects more than a symptom list. Structure it in five parts.

1. Anthropometrics and vital signs

• Measured height and weight, with the date and method recorded
• Calculated BMI shown in the chart, not left implicit
• Waist circumference where your protocol uses it
• Blood pressure and heart rate at baseline
• Weight history: highest adult weight, recent trajectory, prior loss attempts and what happened

2. Medical history relevant to this drug class

• Thyroid history, including any nodules, prior thyroid surgery, and calcitonin testing
• Family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
• Pancreatitis, gallbladder disease, and prior cholecystectomy
• Diabetes status and, where relevant, retinopathy history
• Gastrointestinal conditions, particularly gastroparesis and inflammatory bowel disease
• Renal and hepatic impairment
• Bariatric surgery history
• Psychiatric history, with specific attention to disordered eating

3. Reproductive status

• Pregnancy status and, for patients who could become pregnant, a documented pregnancy test where your protocol requires it
• Contraception in use, and counselling on the interaction between delayed gastric emptying and oral contraceptive absorption
• Pregnancy intention within the coming year, and the washout interval you would advise
• Breastfeeding status

4. Complete medication and supplement list

Reconciled, not merely collected. See the interaction section below.

5. Goals, expectations, and understanding

What does the patient believe this medication does, how long do they expect to take it, and what do they expect to happen when they stop? A patient who says "a few months and then I'll be fine" has revealed a counselling gap that will become an adherence problem and, eventually, a dissatisfaction complaint.

Absolute Contraindications: The Non-Negotiable Stops

These override eligibility completely. A patient can meet every BMI and comorbidity criterion and still be someone this class of drug should not be given to.

• Personal or family history of medullary thyroid carcinoma. This is the boxed warning for the GLP-1 receptor agonists used in weight management, derived from rodent thyroid C-cell tumour findings. "Family history" means first-degree relatives at minimum, and the question has to be asked in those words rather than folded into a general "thyroid problems?" prompt.
• Multiple endocrine neoplasia syndrome type 2. Same basis, same absolute exclusion.
• Prior serious hypersensitivity to the agent or class, including anaphylaxis or angioedema.
• Pregnancy. These agents are not used for weight management in pregnancy, and therapy should be discontinued when pregnancy is discovered or planned. Your protocol should state the interval before conception at which you advise stopping, based on the specific agent's characteristics.
• Active breastfeeding, absent a specific and documented decision by the prescriber with the patient.

Two practical points. First, these must be screened by direct question with the answer recorded — a blank field is not a negative finding, and reviewers treat it as an unasked question. Second, when a patient discloses one of these, the decline and the reason belong in the chart. A documented refusal is one of the most protective entries a weight-management practice can accumulate, because it is affirmative evidence that the screening step is real.

Relative Contraindications: Where Clinical Judgment Actually Lives

Absolute contraindications are easy because they require no judgment. The relative ones are where a screening protocol either helps a clinician think or fails to.

• History of pancreatitis. Not an automatic exclusion, but it demands an explicit risk discussion, a recorded decision, and a lower threshold for investigating abdominal pain during therapy.
• Gallbladder disease. Rapid weight loss of any cause raises gallstone risk. Patients with a gallbladder still in place and a history of biliary symptoms need counselling and a plan for what symptoms mean.
• Gastroparesis and severe gastrointestinal motility disorders. These agents slow gastric emptying by design. In a patient whose stomach already empties poorly, that is an unfavourable mechanism.
• Type 2 diabetes on insulin or a sulfonylurea. Not an exclusion, but hypoglycaemia risk rises materially and the background regimen usually needs adjustment by whoever manages it. This is a coordination obligation, not a solo decision.
• Diabetic retinopathy. Rapid glycaemic improvement has been associated with transient worsening. Existing retinopathy warrants ophthalmology input before starting.
• Significant renal or hepatic impairment. Dehydration from gastrointestinal side effects can precipitate acute kidney injury in patients with limited reserve.
• Age extremes. Adolescent prescribing has its own approval landscape and generally sits outside a med spa's appropriate scope. Older adults carry sarcopenia and fall risk that a weight-loss-only framing ignores.
• Prior bariatric surgery. Altered anatomy changes tolerability and nutritional risk, and coordination with the surgical team is the defensible course.
• Low baseline BMI with body image concerns. Discussed below, and the most commonly missed exclusion in aesthetic settings.

For each of these the standard is the same and it is not "avoid": it is that a clinician noticed, weighed it, recorded the reasoning, and adjusted the plan or the monitoring accordingly.

Medication Reconciliation and Interaction Screening

Collecting a medication list is not reconciliation. Reconciliation means comparing what the patient reports against what they actually take, resolving discrepancies, and acting on what the combined list implies.

The interactions that matter most in this class:

• Insulin and sulfonylureas. The principal hypoglycaemia risk. Dose reduction of the background agent is frequently required, and it should be made by the clinician managing that therapy, with your communication documented.
• Oral medications with narrow therapeutic windows. Delayed gastric emptying alters absorption timing. Thyroid replacement, anticoagulants and anticonvulsants deserve attention and, where appropriate, monitoring.
• Oral contraceptives. Counselling on absorption is part of the reproductive discussion, particularly around dose escalation and periods of vomiting.
• Other weight-loss agents. Stacking a GLP-1 with stimulant anorectics, other incretin therapies, or unregulated peptides obtained elsewhere is a common and under-asked risk. Ask specifically about products bought online.
• Supplements. Patients routinely omit these. Ask by category — herbal, weight-loss, hormonal — rather than open-endedly.

Record the reconciliation itself, not just the list. A note that says "medication list reviewed; metformin continued, no interaction concerns identified; patient advised to separate levothyroxine dosing" demonstrates a clinician did something. A list with no commentary does not.

Baseline Labs: What to Order and Why

There is no single mandated panel, and your protocol should say what you do and why rather than borrow someone else's list. A defensible baseline for a weight-management program typically includes:

• Comprehensive metabolic panel — renal function, hepatic enzymes, electrolytes, glucose
• HbA1c — identifies undiagnosed diabetes or prediabetes and changes both the monitoring plan and the counselling
• Lipid panel — establishes the comorbidity picture and gives you an outcome to track beyond weight
• Thyroid function — screens for a contributing cause of weight change
• Complete blood count — general baseline
• Pregnancy test where clinically indicated
• Lipase or amylase where pancreatitis history makes a baseline useful

Two rules make labs defensible rather than decorative. First, results must be reviewed and the review documented before therapy begins — ordering labs and starting the patient before anyone reads them is worse than not ordering them, because it evidences a process that exists only on paper. Second, if you deviate from your own protocol, record why. "Labs from six weeks ago obtained from primary care and reviewed" is a perfectly good entry. Silence is not.

Documenting Medical Necessity So It Survives Review

Medical necessity is not a box to tick. It is a short piece of reasoning that connects this patient's facts to this treatment decision, and it is the single entry that most distinguishes a defensible chart from a vulnerable one.

A weak entry looks like this: "Patient desires weight loss. BMI 32. Started semaglutide 0.25 mg weekly."

A strong entry looks like this: "46-year-old with measured BMI 32.4 and diagnosed hypertension on lisinopril. Highest adult weight 218 lb; two prior structured attempts at lifestyle modification with 8–10 lb loss and regain within a year. No personal or family history of MTC or MEN2; no pancreatitis, no gallbladder disease, not pregnant, not breastfeeding, using an IUD. Medication list reconciled; no insulin or sulfonylurea. Baseline CMP, HbA1c 5.9%, lipids and TSH reviewed today. Discussed mechanism, expected gastrointestinal effects, boxed warning, the likelihood of weight regain on discontinuation, and the intended duration of therapy. Patient elects to proceed. Initiating at the lowest dose with reassessment at four weeks."

The second version takes ninety seconds to write and answers, in advance, nearly every question a reviewer would ask. Build it as a structured template so that clinicians are prompted through the elements — but leave the reasoning fields free-text. Templates that auto-populate the rationale produce a hundred identical charts, which is its own finding.

Informed Consent for GLP-1 Therapy

A general aesthetic consent does not cover this. GLP-1 consent should be a distinct document, signed and dated, that addresses:

• The specific product being administered, by name, and whether it is an approved product or a compounded preparation
• Whether the use is on-label or off-label for this indication
• Mechanism of action in plain language
• Common adverse effects: nausea, vomiting, diarrhoea, constipation, injection site reactions, fatigue
• Serious risks: pancreatitis, gallbladder disease, hypoglycaemia in combination with certain agents, aspiration risk around anaesthesia, and the boxed warning regarding thyroid C-cell tumours
• Loss of lean mass alongside fat mass, and the role of protein intake and resistance training
• The likelihood of weight regain after discontinuation, stated honestly
• Pregnancy risk and the requirement to discontinue before conception
• The monitoring schedule and the patient's obligations within it
• Cost, refill policy, and an explicit statement that no particular result is guaranteed
• Alternatives, including lifestyle programs, other pharmacotherapy, and referral for surgical evaluation

Where a compounded preparation is used, the consent must say so in terms a patient understands. A consent describing an approved product when something else was administered is worse than no consent at all, because it converts a documentation gap into evidence of misrepresentation.

Screening for What the Drug Cannot Fix

Two screens are routinely skipped in aesthetic settings, and both generate the complaints that are hardest to defend.

Disordered eating

An appetite-suppressing medication administered to a patient with active restrictive eating pathology is a foreseeable harm. Aesthetic practices see a self-selected population, and normal-weight patients who present convinced they need to lose weight are exactly the group at risk. Use a brief validated screening instrument, ask directly about restriction, bingeing and compensatory behaviours, and be prepared to decline and refer. A practice that has never declined anyone on these grounds has almost certainly missed someone.

Expectation and understanding

Ask what the patient thinks will happen when they stop. The honest answer — that appetite and, for most people, a substantial share of the weight return — needs to be delivered at intake rather than at month nine. Patients who understood the trajectory from the beginning do not file complaints about it. Patients who were sold a cure do.

How to Decline a Patient Properly

Declining is a clinical act and deserves the same documentation as approving.

1. State the reason in the chart, specifically. "Declined: reported first-degree family history of medullary thyroid carcinoma" is a complete record. "Not a candidate" is not.
2. Explain it to the patient in plain terms, and note that you did.
3. Offer an alternative pathway. Referral to primary care or endocrinology, a non-pharmacological program, or reassessment after a specified condition is addressed. A decline with a next step is care; a decline without one feels like rejection and generates complaints.
4. Handle deposits and prepayments cleanly. Refund policy for patients who screen out should be settled in advance and stated in writing. Retaining money from a patient you refused to treat is the fastest route to a complaint that starts with billing and ends with a records request.
5. Do not let the patient re-enter through a different door. If a declined patient reappears with a different intake form and a different prescriber, your program has a systems failure that will look deliberate on paper.

Eligibility Is Not a One-Time Event

Screening at intake and never again is a common structural gap. Circumstances change, and each change is a re-screening trigger:

• The patient becomes pregnant or begins trying to conceive
• New medications are started elsewhere, particularly insulin or a sulfonylurea
• A new diagnosis appears — pancreatitis, gallbladder disease, thyroid nodule
• BMI falls to a point where continued treatment for weight loss is no longer clinically indicated
• Adverse effects recur or escalate despite dose adjustment
• Response is inadequate at an adequate dose after an adequate trial
• The patient's goals shift toward maintenance, which is a different conversation with different consent

Build the re-screen into the visit template so it happens by default rather than by memory.

Off-Ramp Criteria: Deciding to Stop

A program that has no written criteria for stopping has, in effect, decided that everyone continues indefinitely. That is not a clinical position and it does not survive review. Your protocol should specify, at minimum:

• Non-response. A commonly used benchmark is inadequate weight reduction after an adequate trial at a therapeutic dose. Whatever threshold you adopt, write it down and apply it.
• Intolerable adverse effects that persist despite dose reduction and supportive management.
• A new absolute contraindication, including pregnancy.
• Goal attainment, with an explicit decision about whether the patient transitions to maintenance therapy, tapers, or stops — and consent appropriate to that choice.
• Non-participation in monitoring. A patient who will not attend reassessment cannot be safely continued, and continuing them anyway is a documented failure of oversight.
• Patient election, with counselling on regain and a documented plan for what follows.

Off-ramping is a clinical event, not an administrative one. Whatever the reason, the chart should show the decision, the counselling, and the plan.

Special Populations Worth a Named Policy

• Patients seeking treatment below the indicated BMI. The most frequent request an aesthetic practice receives and the one with the least clinical support. Your policy should be written before the request arrives, because it is much harder to hold a line invented in the room.
• Patients on a GLP-1 obtained elsewhere. Establish your own screening record before assuming care. Inheriting a patient does not inherit a defensible chart.
• Patients with an upcoming procedure or anaesthesia. Delayed gastric emptying has anaesthesia implications. Patients should be told to disclose this therapy to any surgeon or anaesthetist, and your protocol should state your pre-procedure guidance.
• Athletes and patients with low body fat, where lean mass loss is a larger proportion of total loss and the risk-benefit balance shifts.
• Patients whose primary care clinician is unaware. Not a barrier, but coordination should be offered and the offer recorded.

Who Is Allowed to Perform the Screening

An intake can be perfectly thorough and still be invalid because the wrong person did it. This is the part of screening that varies most by state, and the part practices most often get wrong by importing a workflow from a jurisdiction with different rules.

Three separate roles are involved, and conflating them is the underlying error:

• Data collection. Taking a height and weight, recording vital signs, and handing a patient a history form. Unlicensed and administrative staff can generally do this, subject to your own training standards.
• Clinical evaluation. Interpreting the history, screening contraindications, forming a judgment about candidacy. This is the practice of medicine. It belongs to a licensed prescriber acting within their authority — a physician, or a nurse practitioner or physician assistant with the prescriptive authority your state grants and under whatever collaboration or supervision it requires.
• The prescribing decision. Issuing the patient-specific prescription. Same authority as above, and it cannot be delegated to someone without it.

The failure mode is a medical assistant working through the intake questionnaire, filling in the contraindication fields based on what the patient says, and a prescriber signing the result later without independent inquiry. Several boards have treated that as prescribing without an adequate evaluation, because the clinical judgment step never happened — only its documentation did.

Nurse practitioner authority is the largest source of state-by-state variation. Some states permit fully independent practice; others require a collaborative agreement with a named physician; others require supervision with defined chart review obligations. Where an agreement is required, it must exist, be current, be signed by both parties, and actually cover weight management — an agreement written for aesthetic injectables does not authorise a GLP-1 program. Physician assistant practice is similarly variable and similarly document-dependent.

Two checks are worth running this month. First, confirm that the collaborative or supervisory agreements on file name the current physician, are within any required review interval, and cover the service line in words. Second, confirm that whoever your staff believe performs the evaluation is the same person your written protocol says performs it. Discrepancies between the SOP and the actual routine are the single most productive thing an investigator finds in staff interviews.

Remote Screening: What a Telehealth Intake Must Capture

Telehealth is lawful for weight-management evaluation in most states, and for a consultation of this kind there is rarely a physical finding a competent remote encounter cannot obtain. What draws regulatory attention is not the medium but the substitution of a form for a clinician.

The distinction regulators draw is between synchronous and asynchronous care. A synchronous encounter means live interaction in which a licensed prescriber applies judgment to a specific person and could, in principle, decline. An asynchronous model in which a patient completes a questionnaire and an approval is generated has repeatedly been characterised as prescribing without an adequate evaluation, because no clinician exercised discretion about that individual.

If your screening happens remotely, the record needs to show more than it would in person:

• That the encounter was live, in what modality, and for how long. Duration is a data point investigators use, and a two-minute encounter documented as a full evaluation invites the obvious inference.
• Where the patient was physically located. The governing licence is generally the one in the patient's state at the time of the encounter, not the state where the clinic or the prescriber sits. Multi-state programs routinely get this wrong, and it is a licensure violation rather than a documentation one.
• How height and weight were obtained. Self-reported at intake is acceptable if identified as such and corroborated at the first in-person visit. Presenting self-reported values as measured is not.
• That the prescriber had and used the authority to decline. A program with an approval rate near one hundred percent will be asked to produce its declines. An inability to produce any is treated as an answer.
• Who obtained the consent, and that the discussion preceded the signature rather than accompanying a checkout flow.

Hybrid models — remote prescriber, in-person injections — are common in med spas and are perfectly defensible. They simply require that the remote half be a real encounter and that the in-person half not quietly become the point at which clinical decisions are made by staff who cannot make them.

Screening Does Not End at Initiation

The titration period is a second screening window, and treating it as purely administrative is a common structural gap. Every reassessment visit is an opportunity to catch what the intake missed and what has changed since.

A reassessment that earns its place covers:

• Tolerance. Severity and trajectory of gastrointestinal effects, hydration, and whether the patient is eating adequately rather than simply eating less.
• Red-flag symptoms. Persistent severe abdominal pain, particularly radiating to the back; right upper quadrant pain; persistent vomiting; symptoms suggesting hypoglycaemia in patients on background diabetes therapy.
• Weight trajectory in context. Rate of loss, and whether it is fast enough to raise gallstone and lean-mass concerns rather than merely satisfying.
• New medications and new diagnoses since the last visit, asked specifically rather than left to volunteering.
• Reproductive status changes.
• Protein intake and resistance training, which are the modifiable levers on lean mass loss and belong in the record as counselling delivered.
• The continuation decision itself. Continuing therapy should appear in the chart as a decision with a reason, not as the default that happens when nobody stops it.

That last point is the one most often missing. A file in which every visit note says "continue current dose" and nothing else does not demonstrate management. A file in which the clinician periodically writes why continuation remains appropriate does.

Where State Rules Change the Screening Itself

Beyond prescriber authority, several state-level variables alter what your intake must do. It is worth confirming each of these for every state you operate in rather than assuming a national standard exists.

• Whether an in-person visit is required before a first prescription, and whether any such requirement has exceptions for established patients.
• Whether a specific good faith examination standard is codified, and what it requires by name — some states enumerate elements, others leave it to professional judgment.
• What must appear in the medical record, and for how long records must be retained. Retention periods commonly run five to ten years and are longer for minors.
• Whether standing orders or protocols must be filed, co-signed, or reviewed at a stated interval.
• What unlicensed personnel may do, which in some states expressly excludes taking a history for clinical decision-making.
• Whether telehealth consent has its own statutory form, separate from treatment consent.

None of this is exotic research. It is an afternoon with your state's medical practice act, nursing board rules, and telehealth statute — and it is far cheaper done before an inquiry than after one.

The Screening Failures That Show Up in Complaints

From the pattern of published board matters and the sequence of requests investigators make, the recurring failures are these:

• BMI taken from a patient-completed form and never verified
• Contraindication fields left blank rather than answered
• Family history of medullary thyroid carcinoma never asked in those words
• Identical rationale text across every chart in the practice
• No documented declines anywhere in the file set
• Consent describing a different product from the one administered
• Labs ordered but not reviewed before initiation
• Screening performed by unlicensed staff and countersigned later
• No re-screening after a pregnancy or a new medication was disclosed
• No written off-ramp criteria, and no patient in the practice who ever stopped

Every one of these is a documentation habit rather than a clinical skill. That is the encouraging part: they are fixable in a fortnight, by anyone willing to redesign an intake form and hold staff to it.

Turning This Into a Workflow

A practical sequence that fits a normal appointment:

1. Pre-visit. Patient completes history and medication list. Staff flag anything that needs prescriber attention before the encounter.
2. Measurement. Height, weight, BMI, blood pressure taken and recorded by clinical staff.
3. Prescriber encounter. Live and documented. Contraindication screen worked through by direct question. Reconciliation completed. Eating-pathology screen administered. Goals and expectations explored.
4. Labs. Ordered or prior results obtained, then reviewed and the review documented before any prescription is issued.
5. Decision. Approve with rationale, decline with reason, or defer pending information — all three written in the chart.
6. Consent. Product-specific document signed after the discussion, not handed over with the intake paperwork.
7. Prescription and plan. Patient-specific prescription issued; titration schedule and reassessment date set before the patient leaves.
8. Re-screen at every visit. Short, structured, and part of the template rather than the clinician's memory.

None of this is exotic. It is the ordinary structure of a medical evaluation, applied consistently to a service line that in many practices grew out of a marketing decision rather than a clinical one. The programs that survive scrutiny are simply the ones where that structure exists on the day the patient is seen, rather than being assembled after somebody asks.

Disclaimer: This article is for educational purposes only and does not constitute legal, regulatory, or clinical advice. Prescribing decisions rest with the licensed clinician responsible for the patient, and scope of practice, delegation, and telehealth rules vary by state. Consult a licensed healthcare attorney and your medical director for guidance specific to your practice.